Comparing 3 Approaches for Making Vaccine Adoption Decisions in Thailand

Document Type: Original Article

Authors

1 Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand

2 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore

3 Asc Academics, Groningen, The Netherlands

4 World Health Organization (WHO), Genève, Switzerland

Abstract

Background
The World Health Organization (WHO) has developed the Total System Effectiveness (TSE) framework to assist national policy-makers in prioritizing vaccines. The pilot was launched in Thailand to explore the potential use of TSE in a country with established governance structures and accountable decision-making processes for immunization policy. While the existing literature informs vaccine adoption decisions in GAVI-eligible countries, this study attempts to address a gap in the literature by examining the policy process of a non-GAVI eligible country.

 
Methods
A rotavirus vaccine (RVV) test case was used to compare the decision criteria made by the existing processes (Expanded Program on Immunization [EPI], and National List of Essential Medicines [NLEM]) for vaccine prioritization and the TSE-pilot model, using Thailand specific data.

 
Results
The existing decision-making processes in Thailand and TSE were found to offer similar recommendations on the selection of a RVV product.

 
Conclusion
The authors believe that TSE can provide a well-reasoned and step by step approach for countries, especially low- and middle-income countries (LMICs), to develop a systematic and transparent decision-making process for immunization policy.

Highlights

 

Supplementary file 1 contains Tables S1-S3 and Supplementary file 2 shows the detailed methodology for estimating the vaccine performance based on decision criteria.

 

Keywords


  1. Pooripussarakul S, Riewpaiboon A, Bishai D, Muangchana C, Tantivess S. What criteria do decision makers in Thailand use to set priorities for vaccine introduction? BMC Public Health. 2016;16:684. doi:10.1186/s12889-016-3382-5
  2. Burchett HE, Mounier-Jack S, Griffiths UK, et al. New vaccine adoption: qualitative study of national decision-making processes in seven low- and middle-income countries. Health Policy Plan. 2012;27 Suppl 2:ii5-16. doi:10.1093/heapol/czs035
  3. Howard N, Bell S, Walls H, et al. The need for sustainability and alignment of future support for National Immunization Technical Advisory Groups (NITAGs) in low and middle-income countries. Hum Vaccin Immunother. 2018;14(6):1539-1541. doi:10.1080/21645515.2018.1444321
  4. Mantel C, Wang SA. The privilege and responsibility of having choices: decision-making for new vaccines in developing countries. Health Policy Plan. 2012;27 Suppl 2:ii1-4. doi:10.1093/heapol/czs041
  5. Wallace L, Kapirir L. How are new vaccines prioritized in low-income countries? a case study of human papilloma virus vaccine and pneumococcal conjugate vaccine in Uganda. Int J Health Policy Manag. 2017;6(12):707-720. doi:10.15171/ijhpm.2017.37
  6. Muangchana C, Thamapornpilas P, Karnkawinpong O. Immunization policy development in Thailand: the role of the Advisory Committee on Immunization Practice. Vaccine. 2010;28 Suppl 1:A104-109. doi:10.1016/j.vaccine.2010.02.043
  7. Expanded Programme on Immunization. Division of Vaccine Preventable Diseases, Ministry of Public Health website. http://dvpd.ddc.moph.go.th/.  Accessed December 27, 2018.
  8. Patcharanarumol W, Panichkriangkrai W, Sommanuttaweechai A, Hanson K, Wanwong Y, Tangcharoensathien V. Strategic purchasing and health system efficiency: a comparison of two financing schemes in Thailand. PLoS One. 2018;13(4):e0195179. doi:10.1371/journal.pone.0195179
  9. Praditsitthikorn N, Teerawattananon Y, Tantivess S, et al. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics. 2011;29(9):781-806. doi:10.2165/11586560-000000000-00000
  10. Tantivess S, Yothasamut J, Putchong C, Sirisamutr T, Teerawattananon Y. The role of health technology assessment evidence in decision making: the case of human papillomavirus vaccination policy in Thailand. Nonthaburi: The Graphico Systems Co., Ltd; 2009.
  11. Mohara A, Youngkong S, Velasco RP, et al. Using health technology assessment for informing coverage decisions in Thailand. J Comp Eff Res. 2012;1(2):137-146. doi:10.2217/cer.12.10
  12. Leelahavarong P, Doungthipsirikul S, Kumluang S, et al. Health Technology Assessment in Thailand: Institutionalization and Contribution to Healthcare Decision Making: Review of Literature. Int J Technol Assess Health Care. 2019:1-7. doi:10.1017/s0266462319000321
  13. HTA glossary. International Network of Agencies for Health Technology Assessment (INAHTA) website.  http://www.inahta.org/.   Accessed August 8, 2019.
  14. Teerawattananon Y, Tritasavit N, Suchonwanich N, Kingkaew P. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. Z Evid Fortbild Qual Gesundhwes. 2014;108(7):397-404. doi:10.1016/j.zefq.2014.06.017 
  15. Botwright S, Hutubessy R, Kahn A, Giersing B. A novel approach to evaluate the value of vaccines from the perspective of low and middle income countries: a conceptual framework and pilot project experience. Unpublished manuscript. World Health Organization; 2019.
  16. Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Alloc. 2006;4:14. doi:10.1186/1478-7547-4-14
  17. National Vaccine Institute Web site. http://www.nvi.go.th/.  Accessed July 4, 2018.
  18. National Drug Information. Thai Food and Drug Administration, Ministry of Public Health Web site. http://ndi.fda.moph.go.th/.  Accessed July 4, 2018.
  19. Health Intervention and Technology Assessment Program. Minutes of stakeholder meeting on 17 May 2018: Introduction to Total Systems Effectiveness (TSE) pilot project in Thailand. Nonthaburi: Health Intervention and Technology Assessment Program; 2018.
  20. Health Intervention and Technology Assessment Program. Stakeholder Dissemination Meeting: Total Systems Effectiveness (TSE) Pilot Project in Thailand. Nonthaburi: Health Intervention and Technology Assessment Program; 2018.
  21. Jauregui B, Janusz CB, Clark AD, et al. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions. Vaccine. 2015;33 Suppl 1:A21-27. doi:10.1016/j.vaccine.2014.12.080
  22. Zehrung D, Jarrahian C, Giersing B, Kristensen D. Exploring new packaging and delivery options for the immunization supply chain. Vaccine. 2017;35(17):2265-2271. doi:10.1016/j.vaccine.2016.11.095
  23. World Health Organization (WHO). WHO Cervical Cancer Prevention and Control Costing (C4P) Tool. Geneva: WHO; 2012.
  24. The Health Economic Working Group. Meeting of the Health Economic Working Group on 22 May 2013. Nonthaburi: Food and Drug Administration, Ministry of Public Health; 2013.